Abstract: SA-PO932
Marijuana Use and CKD in an Urban Population
Session Information
- CKD: Clinical, Outcomes, Trials - III
November 09, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2102 CKD (Non-Dialysis): Clinical, Outcomes, and Trials
Authors
- Alvarado, Flor, Johns Hopkins University, Baltimore, Maryland, United States
- Han, Dingfen, Johns Hopkins University, Baltimore, Maryland, United States
- Zonderman, Alan B., Intramural Research Program, NIA, NIH, Baltimore, Maryland, United States
- Evans, Michele Kim, National Institutes of Health/National Institute on Aging, Baltimore, Maryland, United States
- Crews, Deidra C., Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Background
Marijuana is the most commonly used illicit drug in the US. Little is known about the relation of marijuana with kidney outcomes. We examined the association of marijuana use and CKD among a cohort of African American and white adults in Baltimore, Maryland.
Methods
We examined baseline data from the Healthy Aging in Neighborhoods of Diversity across the Life Span study. Marijuana use was self-reported and defined as never, former or current. CKD outcomes were prevalent reduced kidney function (eGFR <60 ml/min/1.73m2) or prevalent albuminuria (urine albumin-to-creatinine ratio (ACR) >=30 mg/g). The association of marijuana use with CKD outcome was examined using multivariable logistic regression.
Results
Among 2352 participants, there were 56% never, 30% former and 14% current marijuana users. Current marijuana users were younger, with fewer yrs of education, and were more likely to be male, African American and use cigarettes, opiates and/or cocaine than never or former marijuana users; but were less likely to have hypertension or diabetes. Overall prevalence of reduced kidney function was 5.3%, with 6.1% of never, 4.6% of former and 3.4% of current marijuana users having reduced kidney function. Overall prevalence of albuminuria was 11.5%, with 12.2% of never, 10.9% of former and 9.7% of current marijuana users having albuminuria. There was no independent association of marijuana use with reduced kidney function or albuminuria.
Conclusion
Marijuana use was prevalent among this urban population. We found no independent association of marijuana use with prevalent CKD. The effects of marijuana use on long term renal outcomes warrants further study.
Logistic regression models of reduced kidney function by marijuana use status
| Model | Marijuana Use | Odds Ratio (95% CI) |
| 1: unadjusted | Never | Ref |
| Former | 0.8(0.5,1.2) | |
| Current | 0.6(0.3,1.0) | |
| 2: adjusted for age, sex, race, education, poverty status | Never | Ref |
| Former | 1.0(0.6,1.6) | |
| Current | 0.8(0.5,1.4) | |
| 3: model2+ hypertension,diabetes | Never | Ref |
| Former | 1.0(0.6,1.7) | |
| Current | 0.9(0.5,1.6) | |
| 4: model3+cigarette, opiate, cocaine use | Never | Ref |
| Former | 0.8(0.4,1.6) | |
| Current | 0.7(0.4,1.3) |